Objective. PM and DM are often complicated by interstitial lung disease (ILD). In this study we aimed to evaluate various serum cytokines in patients with PM/DM with ILD so as to clarify the differences in pathophysiology between anti-melanoma differentiation-associated gene 5 antibody-associated ILD (anti-MDA5-ILD) and anti-aminoacyl tRNA synthetase antibody-associated ILD (anti-ARS-ILD).
Introduction
PM and DM are idiopathic inflammatory myopathies that are characterized by inflammation of the muscles, skin, lungs and heart [1, 2] . PM and DM are classified as autoimmune diseases because several types of myositis-specific autoantibody (MSA) are detected and immunosuppressive therapy such as corticosteroids is effective [3] . PM and DM are occasionally complicated by interstitial lung disease (ILD) [4] . ILD is one of the prognostic factors in PM/DM [5] .
With regard to cytokines, IL-1a, IL-1b, IL-18, TNF-a, IFN-a and IFN-g are highly expressed in the muscle tissues of PM/DM patients [6] . Dendritic cells, macrophages, lymphocytes, muscle fibres and endothelial cells of capillaries synthesize these cytokines in the muscle tissues of patients with PM/DM. In ILD with PM/ DM, it has been reported that serum CRP and the IFN-g-inducible chemokines C-X-C motif ligand 9 (CXCL9) and CXCL10 are associated with anti-Jo-1 antibodyassociated ILD in which myositis is frequently complicated [7] . Serum biomarkers such as cytokines and chemokines could be affected by the whole disease status, including myositis, dermatitis and ILD, in PM/DM. However, the precise differences in the cytokine profiles between myositis and ILD in PM/DM remain unknown.
In PM/DM, complication with ILD is associated with anti-aminoacyl-tRNA synthetase (ARS), including Jo-1 antibody or anti-melanoma differentiation-associated gene 5 (MDA5) antibody [4, 8] . In particular, rapidly progressive ILD (RP-ILD) is an intractable and life-threatening complication. Clinically amyopathic DM (CADM) patients with anti-MDA5 antibodies have frequent complications with RP-ILD, especially in Japan [911] , where it is classified as acute interstitial pneumonia and reflects diffuse alveolar damage upon pathological examination. In contrast, chronic ILD is frequently observed in anti-ARS antibody-associated PM/DM, which responds well to treatment with corticosteroids. The response to treatment and the mortality rate are different between anti-MDA5 antibody-associated ILD (anti-MDA5-ILD) and anti-ARS antibody-associated ILD (anti-ARS-ILD) [4] . Hyperferritinaemia is usually revealed in RP-ILD with anti-MDA5 antibodies but not in anti-ARS antibody ILD [10, 11] . Although the pathogenesis of RP-ILD with anti-MDA5 antibodies has been tentatively attributed to a cytokine storm triggered by a viral infection, especially in the skin and lungs, its exact mechanism is unknown [10, 12] . In addition, the differences in pathophysiology between these two antibody-associated ILD subsets remain unknown.
Therefore we investigated the characteristics of the cytokine profiles in PM/DM with and without ILD. In addition, we compared the cytokine profiles of anti-MDA5 antibody ILD and anti-ARS antibody ILD and clarified the differences in pathophysiology between these two subsets of patients.
Patients and methods

Patients
In this study, patients who were admitted to Tokyo Women's Medical University Aoyama Hospital from 1992 to 2010 were retrospectively examined. We found that 124 patients had been diagnosed with PM, DM or CADM. Of these 124 patients, 78 and 46, respectively, were complicated with and without ILD. Of the 78 patients with ILD, anti-ARS antibodies and anti-MDA5 antibodies were detected in 17 and 14, respectively. To clarify the differences in pathophysiology and cytokine profile between anti-MDA5 antibody ILD and anti-ARS antibody ILD, patients without either anti-MDA5 or anti-ARS were not enrolled in this study. Serum samples were obtained from 11 anti-ARS antibody-positive patients and 10 anti-MDA5 antibody-positive patients. Of 46 patients without ILD, sera were obtained from 17 patients. In 10 patients with anti-MDA5 antibody ILD or anti-ARS antibody ILD and 29 without ILD, the volume of the serum samples was too small to measure various cytokines. These 38 patients were enrolled in the present study. They were diagnosed as having PM/DM or CADM based on the criteria of Bohan and Peter [13] or Sontheimer [14] , respectively. Specific rashes, including heliotrope rash, Gottron's sign or Gottron's papules, were used to define DM and CADM. In general, CADM patients present with typical skin lesions and amyopathy or hypomyopathy for >6 months. A subset of the CADM group in this study included patients who developed ILD within the first 6 months of the study. All of the 38 enrolled patients suffered from skin rashes, myopathy or respiratory symptoms (or a combination thereof).
In all of the enrolled patients, disease status was active upon admission, so the physicians decided to begin immunosuppressive therapy or to increase the intensity of therapy, such as treating with intermediate or high-dose prednisolone or adding additional immunosuppressive agents. Disease duration was defined as the time between the appearance of PM/DM-associated symptoms and admission. The clinical data were obtained from medical records at the time the serum samples were obtained. In addition, serum was obtained from 15 healthy controls (HCs). This study was approved by the ethical committee of Tokyo Women's Medical University. All patients and controls provided written informed consent according to the Declaration of Helsinki.
Evaluation of muscular and extra-muscular manifestations
Myositis was evaluated by manual muscle testing, creatine kinase (CK) and electromyography. MRI and muscle biopsy of the extremities was carried out if necessary. Dermatitis and arthritis were evaluated by physical examination. If necessary, dermatologists evaluated the skin eruptions and performed a skin biopsy. Pulmonary disease was assessed by chest radiography and high-resolution CT. Pulmonary function was also evaluated if findings were revealed in the lung. Cardiac function was evaluated by electrocardiography and echocardiography. Scintigram and myocardial biopsy were conducted if necessary. Enteropathy was assessed by gastrointestinal endoscopy and colonoscopy. A malignancy survey was performed for all of the patients.
Evaluation of pulmonary function and classification of ILD Pulmonary function was evaluated from the arterial oxygen tension (PaO 2 )/fractional inspired oxygen (F i O 2 ) ratio (i.e. P/F ratio), alveolararterial oxygen difference (A-aDO 2 ) and vital capacity percentage (%VC). RP-ILD was defined as a progressive dyspnoea that developed rapidly, over days to weeks, after the onset of respiratory symptoms. Chronic ILD was defined as a progressive dyspnoea that developed slowly, over months [15, 16] .
Evaluation of disease activity for PM/DM/CADM Disease activity was evaluated using the myositis disease activity core set, which the International Myositis Assessment and Clinical Studies (IMACS) group has proposed and recommended [3, 17, 18] . Muscular symptoms www.rheumatology.oxfordjournals.org and extra-muscular complications were measured using the myositis activity assessment visual analogue scales (MYOACT) and the myositis intention-to-treat activity index (MITAX). Constitutional, cutaneous, skeletal, gastrointestinal, pulmonary, cardiac and muscular disease activity were included in both the MYOACT and MITAX. The MITAX score was the MITAX sum score divided by the total score of 63 points. The details of clinical information required for the estimation of MITAX and MYOACT were available in the medical records. The MITAX and MYOACT were estimated retrospectively by physicians in charge or evaluators who were blinded to the results of cytokine profiles in reference to the medical records information.
Evaluation of MSAs
Anti-MDA5 antibody was detected with the use of an ELISA using recombinant MDA5 as an antigen, as described previously [9] . Anti-ARS antibodies, including Jo-1, EJ, PL-7, PL-12 and OJ, were measured with RNA immunoprecipitation assays. The other MSAs were detected through immunoblots using the Myositis Profile Euroline antibody test system for the in vitro determination of antibodies against myositis-associated antigens in human serum (Euroimmun, Lü beck, Germany). 
Measurement of cytokines
Statistical analysis
Statistical analyses were performed using the chi-square test for the comparison of frequencies, Fisher's exact test was used when appropriate and the MannWhitney U test was used for the comparison of median values. Correlation coefficients were established by employing Spearman's correlation coefficients. Multiple linear regression analysis was performed when appropriate. The Wilcoxon signed-rank test was performed when comparing the cytokine levels of patients with active ILD and the cytokine levels after improvement. The data were analysed using JMP software (SAS Institute, Cary, NC, USA). P-values <0.05 indicated statistical significance.
Results
Clinical characteristics of the enrolled patients
A total of 38 patients was enrolled in this study ( Table 1) . The median age was 52 years and 74% of the participants were female. The number of PM, DM and CADM cases was 12, 14 and 12, respectively. The median disease duration was 4 months. The frequency of ILD, cardiomyopathy and malignancy was 55%, 13% and 3%, respectively. The positivity rate of anti-ARS antibody, anti-Mi-2 antibody, anti-MDA5 antibody and anti-signal recognition particle (SRP) antibody was 32%, 3%, 26% and 5%, respectively. The median MITAX score was 0.19.
Comparison of cytokine levels in PM/DM/CADM and HCs
To investigate the characteristics of cytokine profiles in all of the PM/DM/CADM patients, the levels of each cytokine were compared in PM/DM/CADM patients and the HCs (Table 2) . Serum IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-a, IFN-a, IFN-g and IP-10 were significantly higher in PM/ DM/CADM patients than HCs. IL-12, IL-13 and IL-17 levels did not differ between PM/DM/CADM patients and HCs.
Correlations between each cytokine level in PM/DM/ CADM We estimated the correlations between each cytokine level in PM/DM/CADM. As shown in Table 3 , IL-1b levels were significantly (P < 0.001) correlated with the levels of IL-2, IL-6, IL-12 and IFN-g. Moreover, the correlation between IL-2 and IL-12 and between IL-6 and TNF-a was significant (P < 0.001). IL-10 levels were significantly (P < 0.001) correlated with the levels of TNF-a, IFN-g and IP-10.
Correlation between cytokine levels and whole disease activity
We evaluated the association between each cytokine level and the MITAX score, which is an indicator of both muscular and extra-muscular disease activity. The MITAX score was significantly correlated with the level of IL-6 (r s = 0.59, P < 0.0001), IL-8 (r s = 0.34, P < 0.05), IL-10 (r s = 0.36, P < 0.05), TNF-a (r s = 0.53, P < 0.0001) and IP-10 (r s = 0.35, P < 0.05). Comparison of clinical characteristics of the non-ILD subset and the ILD subset
To investigate the cytokine profiles in PM/DM/CADMassociated ILD, clinical characteristics and cytokine levels were compared between the non-complicating ILD (non-ILD) subset and the ILD subset (Table 4) . Regarding the differences between the two subsets, the constitutional visual analogue scale (VAS), cutaneous VAS and MITAX scores were higher in the ILD subset than in the non-ILD subset. However, CK levels and the muscular VAS score were lower in the ILD subset. These findings could reflect the high frequency of CADM in the ILD subset.
Analysis of cytokines that contribute to ILD in PM/ DM/CADM
The levels of IL-4, IL-6, IL-8, IL-10, TNF-a and IP-10 were significantly higher in the ILD subset than the non-ILD subset (Table 4) . To reveal the cytokines that contribute to ILD, multiple linear regression analysis was performed. The existence of ILD was the dependent variable. Independent variables included the above-described cytokines determined to be significant by univariate analysis. In addition, the multivariate analysis was adjusted with the muscular VAS and cutaneous VAS to reveal specific cytokines associated with pulmonary disease activity. TNF-a was the cytokine that was most significantly associated with ILD in PM/DM/CADM [P = 0.0006, odds ratio (OR) 1. Comparison of cytokine profiles of the anti-ARS-ILD subset and anti-MDA5-ILD subset
To reveal the pathophysiological differences between anti-ARS-ILD and anti-MDA5-ILD, clinical characteristics and cytokine levels were compared between the two subsets. As shown in Table 5 , in the anti-MDA5-ILD subset, the frequency of CADM complicated with RP-ILD was high and PM was not observed. The cutaneous VAS and pulmonary VAS scores were significantly higher in the anti-MDA5-ILD subset than in the anti-ARS-ILD subset, although the MITAX score and pulmonary function did not differ between the two subsets.
Regarding the cytokine levels, the IL-8 level was significantly higher in the anti-MDA5-ILD subset than the anti-ARS-ILD subset. Lower levels of IL-4 and higher levels of IL-10 and IFN-a were found in the anti-MDA5-ILD subset than in the anti-ARS-ILD subset, although these differences did not reach significance (P < 0.10). IL-6, TNF-a and IP-10 levels were high in both subsets and did not significantly differ between the two subsets. Statistical analyses were performed using Spearman's rank correlation coefficient. *P < 0.05, **P < 0.01 and ***P < 0.001. Statistical analyses were performed using the MannWhitney U test to compare the PM/DM/CADM subset and HCs. **P < 0.01 and ***P < 0.001. IQR: interquartile range; CADM: clinically amyopathic DM; HCs: healthy controls; IP-10: IFNg-inducible 10-kDa protein.
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To determine the cytokines that contributed to the pathophysiology of anti-MDA5 antibody ILD and anti-ARS antibody ILD, multiple linear regression analysis was performed. The existence of anti-MDA5 antibody positivity was the dependent variable. Independent variables included IL-4, IL-8, IL-10 and IFN-a levels, for which the P-value was <0.10 in the univariate analysis. IL-8 was the cytokine that was most significantly associated with anti-MDA5 antibody ILD (P = 0.0006, OR 1.5, CI 1.1, 3.0). In addition, IL-4 level was inversely associated with anti-MDA5 antibody ILD (P = 0.01, OR 0.8, CI 0.6, 0.98). Moreover, the ratio of serum IL-4 to IFN-g, which may reflect a balance between T helper 1 (Th1) and 2 (Th2) cells, was lower in anti-MDA5 antibody ILD (median 0.16) than in anti-ARS antibody ILD (median 2.0), although this difference was not significant (P = 0.07).
Prediction of fatal outcome due to ILD by serum cytokine levels
To predict a fatal outcome due to ILD, we estimated the cut-off levels of serum cytokines with all the ILD patients using a receiver operating characteristic (ROC) curve. The predictive cytokines included IL-8, IL-10 and IFN-a, which had high levels in anti-MDA5 antibody ILD. Fatal outcome due to ILD was found in four patients with anti-MDA5 antibody ILD, but none were found in patients with anti-ARS-ILD. The cut-off levels of serum cytokines (sensitivity, specificity) were as follows: IL-8, 29.7 pg/ml (100%, 94%); IL-10, 13.1 pg/ml (100%, 71%); IFN-a, 37.0 pg/ml (100%, 18%). Serum IL-8 was the most useful predictive cytokine for fatal outcome due to ILD.
In most patients without ILD, the cytokine levels were below the cut-off values, but a few patients had cytokine levels above the cut-off values. In the non-ILD subset with IL-8 levels above the cut-off value, all three patients had DM. All patients without ILD survived even if cytokine levels were above the cut-off values.
Comparison of cytokine profiles in active ILD status and improved ILD status
Clinical data and sera were also obtained after improvement of ILD in six patients (three with anti-ARS antibody and three with anti-MDA5 antibody). We compared disease activity and cytokine levels between the active ILD status time point and the improved ILD status time point in these six ILD patients.
As shown in Fig. 1 , the MITAX and pulmonary disease activity VAS scores were significantly (P < 0.05) lower when the ILD status improved than when active, as expected. IL-6, TNF-a, IFN-a, IFN-g and IP-10 levels were significantly (P < 0.05) decreased when the ILD status improved (Fig. 1) . IL-1b, IL-2, IL-4 and IL-8 levels also decreased after improvement of ILD, although the differences were not significant.
Discussion
We have identified the cytokine profiles associated with PM, DM and CADM. IL-6, IL-8, IL-10, TNF-a and IP-10 levels were associated with the global disease activity of PM/DM/CADM in the present study. These results were consistent with those of previous studies [19, 20] . Serum biomarkers could be affected by the activity of several diseases, including dermatitis, myositis and ILD in PM/ DM/CADM. The present study demonstrated that TNF-a was the most significant cytokine in ILD with PM/DM/ CADM. In idiopathic pulmonary fibrosis (IPF), activated macrophages and TNF-a play a crucial role in pulmonary inflammation and/or fibrosis [2123] . We speculate that TNF-a produced by activated macrophages and mononuclear cells could be associated with the development of ILD as well as myositis and dermatitis with PM/DM/ CADM. In general, activated macrophages are classified into three subsets: classically activated macrophages, wound-healing macrophages and regulatory macrophages [24] . Classically activated macrophages produce pro-inflammatory cytokines such as IL-1 and IL-6. IFN-g produced by Th1 cells or natural killer cells, along with TNF-a from antigen-presenting cells, can stimulate classically activated macrophages. In contrast, wound-healing macrophages play a role in the release of pro-fibrotic mediators and in the deposition of collagen. IL-4 produced by Th2 cells or granulocytes can promote the activation of wound-healing macrophages. IL-4 is the most powerful inducer of wound-healing macrophages in IPF patients [25] . The imbalance between classically activated macrophages and wound-healing macrophages might cause the differences in pathophysiology between RP-ILD and chronic ILD in PM/DM/CADM.
This study also revealed differences in the cytokine profiles of anti-ARS-ILD and anti-MDA5-ILD. In patients with these antibody types, it has been reported in previously that clinical manifestations, response to therapy and prognosis of ILD vary in PM and DM [4] . Anti-MDA5-ILD is more intractable and life threatening than anti-ARS-ILD, especially in East Asia. Until now, the details of these differences in pathophysiology have remained unknown. We found that IL-4 levels were low in anti-MDA5-ILD patients and HCs, whereas they were higher in anti-ARS-ILD patients. The ratio of serum IL-4 to IFN-g was also lower in anti-MDA5 antibody ILD than in anti-ARS antibody ILD. In anti-MDA5-ILD, the cytokine balance was skewed more dominantly to a Th1 profile than in anti-ARS-ILD. The balance between Th1 and Th2 cytokines may contribute to the differences in activated macrophage type, the severity of pulmonary inflammation and the response to treatment in anti-ARS-ILD and the anti-MDA5-ILD.
However, IL-8 levels were higher in anti-MDA5-ILD than anti-ARS-ILD. As the present study indicates, serum IL-8 is a useful predictor for fatal outcome due to ILD. The IL-8 levels in bronchoalveolar lavage fluid correlated with the severity of pneumocystis pneumonia [26] . In addition, plasma IL-8 levels were associated with the severity of acute lung injury (ALI)/ARDS [27, 28] . IL-8-related Values are given as median (interquartile range) unless stated otherwise. Statistical analyses were performed using the MannWhitney U test and Fisher's exact test. *P < 0.10, **P < 0.05 and ***P < 0.01. ARS: aminoacyl-tRNA synthetase; ILD: interstitial lung disease; MDA5: melanoma differentiation-associated gene 5; RP-ILD: rapidly progressive ILD; MITAX: myositis intention-to-treat activity index; P/F ratio: arterial oxygen tension (PaO 2 )/fractional inspired oxygen (F i O 2 ) ratio; A-aDO 2 : alveolar-arterial oxygen difference; %VC: vital capacity percentage; IP-10: IFN-g-inducible 10-kDa protein; CK: creatine kinase.
www.rheumatology.oxfordjournals.org neutrophil elastase may play a role in the pathogenesis of ALI/ARDS. Alveolar macrophages activated by some antigens, microbes and autoimmune stimuli are induced to produce IL-8, which stimulates neutrophils and thereby induces fibrosis in the lungs [29] . Diffuse alveolar damage has been found in both ALI/ARDS and anti-MDA5-ILD. The common pathophysiology could result from the activated alveolar macrophages and neutrophils in these two diseases. IL-8 could be a key cytokine and a target for therapy in anti-MDA5-ILD. IFN-a and IFN-a-inducible genes are associated with the whole disease status of PM/DM [30, 31] . Serum IFNa levels were also high in anti-MDA5-ILD in the present study. Previous studies have reported that IFN-a may be more closely and strongly associated with pulmonary disease status in anti-MDA5-ILD [12] . The MDA5 protein plays a role in the innate immune system. MDA5 initially recognizes picorna viruses, such as the Coxsackie virus, and induces antiviral responses by inducing the production of type I IFNs and TNF-a [32] . Hyperferritinaemia is revealed not only in macrophage activation syndrome (MAS), but also in RP-ILD with anti-MDA5 antibodies [10, 11, 33] . The pathophysiology of MAS involves the lack of regulation of T lymphocytes and excessive production of cytokines such as TNF-a, IL-1b IL-6 and IL-18, resulting in the activation of macrophages. The activated promotion of IFN-a and TNF-a via MDA5 protein may cause stimulation of Th1 cells and macrophages as well as the development of a cytokine storm in the lungs in patients with anti-MDA5-ILD.
There are several limitations to this study. First, this study was retrospectively conducted. The MITAX and MYOACT scores were retrospectively estimated. Secondly, patients with PM and DM were combined and classified into the non-ILD subset. In general, the pathophysiology of PM is distinct from that of DM, although some cytokines, including IL-6, TNF-a and IP-10, are commonly associated with the inflammation of muscle tissue in both PM and DM. Thirdly, PM/DM-ILD patients without either anti-MDA5 or anti-ARS were not enrolled in this study. Some results might be not valid in the whole aspect of PM/DM-ILD. Finally, some patients were being treated with intermediate or high-dose prednisolone at the time of serum collection. These medications could influence the measurement of cytokine levels, although almost all patients were being treated with low-dose prednisolone (0.10.2 mg/kg/day) or with symptomatic therapy when serum was collected.
In conclusion, IL-6, IL-8, IL-10, TNF-a and IP-10 are associated with global disease activity in PM, DM and CADM. These cytokine levels were high, especially in ILD with PM/DM. Serum IL-8 levels and the balance between IL-4 and IFN-g may contribute to the differences in pathophysiology between chronic ILD (anti-ARS-ILD) and RP-ILD (anti-MDA5-ILD).
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FIG. 1 Comparison of disease activity and cytokine levels in patients with active ILD status and improved ILD status
Statistical analyses were performed using the Wilcoxon signed-rank test to compare the active ILD status group and the improved ILD status group. MITAX, pulmonary VAS, IL-6, TNF-a, IFN-a and IP-10 levels were significantly (P < 0.05) decreased when the ILD status improved. MITAX: myositis intention-to-treat activity index; VAS: visual analogue scale; IP-10: IFN-g-inducible 10-kDa protein.
